Saraiva, José Francisco Kerr
Franco, Denise
Funding for this research was provided by:
Novo Nordisk Farmacêutica do Brasil LTDA
Article History
Received: 13 August 2021
Accepted: 7 November 2021
First Online: 15 December 2021
Declarations
:
: Not applicable.
: Not applicable.
: Dr. José Francisco Kerr Saraiva is the national leader of the SOUL and SELECT trials. He is part of the Novo Nordisk Global Expert Panel. He receives fees to give lectures by Novo Nordisk, Lilly, Novartis, Boehringer Ingelheim, Merck, and Sharp & Dohme. Dr. Denise Franco is the principal investigator in cardiovascular risk studies of oral and injectable semaglutide. She is part of the Novo Nordisk, Medtronic, Sanofi, Abbott, and Biomm advisory boards. She receives fees to give lectures by Novo Nordisk, Lilly, Novartis, AstraZeneca, Medtronic, Biomm, Sanofi, Abbott, and Roche.